Vertex's triple combination CF drug meets main late-stage trial goals

In this article:

Feb 5 (Reuters) - Vertex Pharmaceuticals experimental triple combination cystic fibrosis (CF) treatment met all late-stage study goals when tested in patients aged 12 years and older, the company said on Monday. (Reporting by Pratik Jain in Bengaluru; Editing by Anil D'Silva)

Advertisement